Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection.

Acta Pharm Sin B

College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University, Zhengzhou 450001, China.

Published: December 2024

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725028PMC
http://dx.doi.org/10.1016/j.apsb.2024.08.009DOI Listing

Publication Analysis

Top Keywords

sunlenca® lenacapavir
4
lenacapavir first-in-class
4
first-in-class long-acting
4
long-acting hiv-1
4
hiv-1 capsid
4
capsid inhibitor
4
inhibitor treating
4
treating highly
4
highly multidrug-resistant
4
multidrug-resistant hiv-1
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!